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Abstract The inhibitor of the Hsp90 chaperone Geldanamycin
has been reported to have several cellular effects, such as
inhibition of v-src activity or destabilization of Raf-1 among
others. We show now that Geldanamycin treatment induces
different phenotypes in different cell lines. In PC12 cells, it
triggers apoptosis, whereas in the murine neuroblastoma N2A, it
induces differentiation with neurite outgrowth. Geldanamycin
effects cannot be mimicked by inhibition of the c-src protein
tyrosine kinases, and nerve growth factor does not protect PC12
cells from apoptosis. Mitogen-activated protein kinase activities
ERK and JNK are activated differently according to cell type: in
PC12 cells JNK is activated, and its inhibition abolishes
apoptosis, but not ERK; in N2A cells, both ERK and JNK are
activated, but with peak activities at different times. ß 2001
Federation of European Biochemical Societies. Published by
Elsevier Science B.V. All rights reserved.
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1. Introduction
Cells in pluricellular organisms are always challenged by
di¡erent signals from the external milieu that direct them to
one of four possible outcomes: proliferation, di¡erentiation,
apoptosis or senescence. The speci¢c signals or inputs towards
these pathways are not always well understood, and almost
never are exclusive for any given pathway. Growth factors
induce proliferation through interaction with tyrosine kinase
receptors and a complex recruitment of protein kinases that
ends up in the induction of gene expression [1,2]. The same
kind of signaling process often also induces di¡erentiation [3].
One interesting property of several signaling pathways is
the association of some of their components with di¡erent
proteins that help to maintain a stable spatial organization,
like sca¡olding proteins [4] or chaperones that help to main-
tain an activatable state. Of these chaperones, the multicom-
ponent Hsp90 system [5] is found complexed with steroid
hormone receptors [6,7], cyclin-dependent kinases [8], src
[9,10], Raf-1 kinase [11,12] or the kinase suppressor of ras
[13]. At least for Raf-1 kinase, it has also shown that
p50cdc37 is an essential component of this protein complex
[14]. It seems, therefore, that Hsp90 has an essential function
in signal transduction in addition to its role in the response to
stress [15^17].
The function of Hsp90 is inhibited by Geldanamycin (GA),
a benzoquinone ansamycin antibiotic previously proposed as
an antitumor drug because its inhibition of v-src and
p185cÿerbBÿ2 tyrosine kinases. Schulte and co-workers have
shown that GA treatment induces destabilization and degra-
dation of Raf-1 kinase mediated by the proteasome [18^21].
The present study shows that GA treatment a¡ects in di¡er-
ent ways various cell lines, and that these e¡ects can be related
in part to the ability of GA to induce degradation of Raf-1.
2. Materials and methods
2.1. Reagents and plasmids
Go«6976, SB203580 and 4-amino-5-(4-chlorophenyl)-7-(tbutyl)pyra-
zolo[3,4-d]pyrimidine (PP2) were from Calbiochem. Myelin basic pro-
tein (MBP) was from Sigma. GA was a kind gift of the Drug Syn-
thesis and Chemistry Brand, Development Therapeutics Program,
division of Cancer Treatment, National Cancer Institute (Bethesda,
MD, USA). Antibodies were from Santa Cruz (Santa Cruz, CA,
USA), except monoclonal antibody against c-src, a gift of Dr. J.
Mart|¤n-Pe¤rez (from this institute). The GST^c-jun(1-79) construct
was supplied by Dr. M. Karin, University of California, San Diego,
CA, USA. Nerve growth factor (NGF) (Sigma) was supplied by Dr.
A. Aranda, from this institute.
2.2. Cell culture
The neuroblastoma cell line N2A, obtained from the European
Culture Collection (ECACC #98121404), was provided by Dr. A.
Pe¤rez-Castillo; PC12 cells were provided by Dr. A. Aranda, both
from our Institute. N2A cells were grown at 37‡C in DMEM supple-
mented with 10% fetal calf serum, 2 mM glutamine and 40 mg/ml
gentamicin; PC12 cells were grown with 5% fetal calf serum and 10%
donor horse serum in the same medium. Cells were subcultured twice
weekly and were renewed every 10 passages. In all cases, cells were
plated 24 h prior to the experiments.
2.3. Measurement of cell death
The extent of apoptosis was quanti¢ed with the Cell Death Detec-
tion ELISA kit from Roche (this kit estimates the amount of cyto-
plasmic, small molecular weight, histone-associated DNA), or by £ow
cytometry [22]; cells were analyzed in a Becton-Dickinson FACScan.
Data are expressed as percentage of propidium iodide-positive cells
with hypodiploid content of DNA.
2.4. Assay of extracellular signal-regulated kinase (ERK) and c-jun
N-terminal kinase (JNK) activities
After appropriate treatments (see individual experiments), approx-
imately 8U105 cells (in 60 mm diameter plates) were washed twice
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with PBS and lysed with 300 Wl of lysis bu¡er (20 mM HEPES, pH
7.5, 10 mM EGTA, 40 mM L-glycerophosphate, 2.5 mM MgCl2,
2 mM o-vanadate, 1 mM DTT, 1% NP-40 and protease inhibitor
mix (10 Wg/ml leupeptin, 10 Wg/ml aprotinin, 10 mM benzamidine
and 1 mM pMSF). Cells were scraped o¡ the plate and incubated
at 4‡C for 20 min. The cell lysate was centrifuged 15 min at 20 000Ug
at 4‡C and the supernatant stored at 370‡C until use. Protein (75^200
Wg) was immunoprecipitated with 5 Wl of polyclonal anti-ERK 2 or
anti-JNK1 antibodies and incubated 1 h at 4‡C. Immunocomplexes
were isolated by incubation with 20 Wl of 50% protein A^Sepharose
(Sigma) in lysis bu¡er for 1 h at 4‡C with gentle end-over-end rota-
tion, and centrifuged for 1 min. Supernatant was discarded and the
beads washed three times (0.5 ml each) with PBS, 2 mM o-vanadate,
1% NP-40, once with 0.1 M Tris^HCl, pH 7.5, 0.5 M LiCl and once
with kinase bu¡er (20 mM HEPES, pH 7.5, 2 mM DTT, 20 mM
L-glycerophosphate, 20 mM p-nitrophenyl phosphate, 20 mM MgCl2,
0.1 mM o-vanadate) without ATP. After the last wash, the beads were
incubated at 30‡C for 20 min in 30 Wl kinase bu¡er plus 20 WM ATP,
1^2 WCi [Q-32P]ATP (4500 Ci/mmol, ICN, Costa Mesa, CA, USA) and
5 Wg MBP for ERK2 or GST^c-jun(1-79) for JNK1. The reaction was
terminated with ¢ve times concentrated sample bu¡er, boiled 3 min
and electrophoresed on 15% (or 10% for JNK1) SDS^polyacrylamide
gels. Gels were brie£y stained and ¢xed, dried and exposed to X-ray
¢lm (Amersham hyper¢lm, Amersham, UK). Activity was quanti¢ed
in a Packard instant imager. Previous experiments performed with
antibodies against both isoforms of ERK showed that ERK1 repre-
sents less than 10% of the total ERK activity in these cells, having the
same activation pro¢les after stimulation with phorbol esters. Simi-
larly, pull down experiments of JNK activity using the GST^c-jun
fusion protein bound to glutathione^Sepharose beads, showed no dif-
ference between total and JNK1 pro¢les. Therefore, only ERK2 and
JNK1 were studied in this work.
2.5. Other methods
Microphotographs were taken with Nomarski optics in a Zeiss
Axiophot microscope. Protein was determined with the BCA protein
Fig. 1. E¡ect of GA on N2A cells. A: Morphological di¡erentiation (C, control cells with no treatment; 3S, cells deprived of serum for 24 h;
GA, cells grown for 24 h in the presence of 2 WM GA); white bar represents 20 Wm. B: Quanti¢cation of N2A cell di¡erentiation after serum
withdrawal or GA treatment; cells were scored as positive when they had processes larger that two cell diameters. Data are expressed as
mean þ standard error of the percentage of cells bearing processes in four randomly chosen photographic ¢elds. C: E¡ect of the c-src inhibitor
PP2 on N2A cell di¡erentiation; cells were treated with GA or deprived of serum as described above in the presence or absence of 5 WM PP2.
Quanti¢cation of di¡erentiated cells was as above. ***P6 0.001 with respect to control cells ; **P6 0.01 with respect to control cells;
rrrP6 0.001 with respect to cells deprived of serum; 7P6 0.05 with respect to cells treated with GA.
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assay reagent (Pierce, Rockford, IL, USA). Gel electrophoresis and
immunoblotting was done according to conventional protocols; anti-
gen detection was done by Enhanced Chemiluminescence (ECL,
Amersham). Statistical analysis, one-way non-paired ANOVA with
Turkey’s post test comparison, was done with the Prism v.2.0a pro-
gram (GrafPad Software).
3. Results
3.1. E¡ect of GA on N2A cells
Treatment of N2A cells with GA resulted in di¡erentiation,
shown by neurite extension (Fig. 1A). This e¡ect is equivalent
to serum deprivation, as shown in Fig. 1A, and in Fig. 1B in a
more quantitative way. This e¡ect cannot be attributed to
c-src inhibition, as a speci¢c inhibitor of src activity, PP2,
had the opposite e¡ect, namely inhibition of di¡erentiation,
as shown in Fig. 1C.
3.2. E¡ect of GA on PC12 cells
When PC12 cells were treated with GA, apoptosis was in-
duced (Fig. 2). Again, this e¡ect was not due to src inhibition,
as PP2 had no e¡ect on the survival of the cells. We checked if
NGF, a well known survival factor for PC12 cells [23], could
protect them from apoptosis induced by GA; as shown in Fig.
2, this is not the case; NGF was unable to induce survival in
the presence of GA, although it was e¡ective against apopto-
sis induced by serum withdrawal.
3.3. GA induces destabilization of Raf-1
As mentioned before, there are several reports that show
that GA treatment destabilizes Raf-1 kinase, allowing its deg-
radation by the proteasome [20]. Fig. 3A shows that Raf-1
disappears upon GA treatment in both cell types after ap-
proximately 9 h of treatment. This e¡ect was speci¢c for
Raf-1, as other important signaling components, like c-src,
c-Myc, ERK2 or JNK1 were not a¡ected by treating the cells
with the drug, as shown in Fig. 3B.
3.4. Mitogen-activated protein kinase (MAPK) pathways are
a¡ected by GA
It has been proposed for PC12 cells that sustained activa-
tion of ERK is su⁄cient for di¡erentiation [2,3], whereas ac-
tivation of JNK and inhibition of ERK are needed for apo-
ptosis triggered by serum withdrawal [24]. We have studied,
therefore, the e¡ect of GA treatment on the activity of these
kinases in N2A and PC12 cells. Fig. 4A shows that, in N2A
cells, ERK activity raises during GA treatment, reaching max-
imum levels around 8 or 9 h after addition of the drug. In the
same experiment JNK levels did not change signi¢cantly dur-
ing the treatment. These results correlate with those obtained
when N2A cells were deprived of serum, a di¡erentiation sig-
Fig. 2. E¡ect of GA on PC12 cells. Cells were, deprived of serum,
treated with 2 WM GA or with PP2 (5 WM) for 48 h in the absence
(open bars) or presence (¢lled bars) of 50 ng/ml NGF, and pro-
cessed for £ow cytometric analysis of apoptosis as described in Sec-
tion 2. Data are expressed as mean þ standard error of three inde-
pendent experiments. ***P6 0.001 with respect to control cells ;
7P6 0.001 with respect to serum-deprived cells.
Fig. 3. Steady-state levels of Raf-1 and other proteins in GA treated
N2A and PC12 cells. A: Disappearance of Raf-1 after treatment
with GA. Individual cultures of N2A (above) or PC12 (below) were
treated with GA, lysed at the indicated times (h) and subjected to
Western blot analysis. B: Levels of di¡erent proteins in cells treated
with GA. Individual cultures of N2A (left) or PC12 (right) were de-
prived of serum or treated with GA and lysed after 24 h. Western
blot analysis was carried out with antibodies against c-src, c-Myc,
ERK2 and JNK1 (C, control cultures; 3S, cultures deprived of se-
rum; GA, cultures treated with 2 WM GA).
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nal for these cells [25], as shown in Fig. 4B; ERK activity has
a steady increase at approximately the same time as with the
treatment with GA, and JNK has a small and transient peak
of activation. At least in the case of serum deprivation, the
sustained ERK activation seems to be determinant for the
di¡erentiation process, since inhibition of the pathway with
the MEK inhibitor PD98059 [26] diminished di¡erentiation by
50% (not shown).
The opposite e¡ect was observed in PC12 cells ; JNK was
activated and reached a maximum at around 12 h of treat-
ment, whereas ERK activity decreased below the basal levels
found in untreated cells, with a similar kinetics of that ob-
served for Raf disappearance (Fig. 5A). When cells were pre-
treated with the JNK inhibitor SB203580 [27] before adding
GA, the induction of apoptosis was completely abolished
(Fig. 5B), demonstrating the involvement of JNK in the in-
duction of apoptosis.
4. Discussion
The results presented in this report show that di¡erent cell
lines respond in di¡erent ways to the inhibition of Hsp90 by
GA. Di¡erences in response to GA, as those that we observe,
have already been pointed out at an organismal level by Ruth-
erford and Lindsquit [15]. These authors proposed Hsp90 as
an evolutionary capacitor, acting as a bu¡er for avoiding ex-
pression of deleterious mutations in normal growth condi-
tions. Should a stress situation take place, the canalization
of Hsp90 to other roles instead of maintaining crucial signal-
ing pathways properly, could permit rapid and profound
changes in relatively short times. A cellular correlate of this
scenario is shown by the di¡erent phenotypes that Hsp90 in-
hibition by GA can trigger in di¡erent cell lines.
We chose two cell lines that are neuronal model systems,
and that behave di¡erently upon serum deprivation; while
N2A cells di¡erentiate [25], PC12 cells enter in apoptosis
[24,28]. N2A cell di¡erentiation induced by withdrawal of
serum resulted in activation of ERK activity, and the same
is true for GA treatment of these cells. Our results of Raf-1
levels and ERK activity are consistent in the sense that we
Fig. 4. Kinetics of ERK2 (open symbols) or JNK1 (closed symbols)
activation in N2A cells after treatment with 2 WM GA in N2A (A)
or serum deprivation (B). ERK2 and JNK1 activities were assayed
as described in Section 2. Activity of both enzymes at time zero was
arbitrarily set to 1.
Fig. 5. Kinetics of ERK2 (open symbols) or JNK1 (closed symbols)
activation in PC12 cells after treatment with 2 WM GA (A). Sup-
pression of apoptosis induced by GA (2 WM) by pretreatment with
SB203580 (25 WM), in PC12 cells (B). Cells were treated for 24 h as
shown in the ¢gure and processed to measure apoptosis with an
ELISA detection kit as described in Section 2. Absorbance at 405
nm measures cytoplasmic, histone-associated low-molecular weight
DNA. Data are expressed as mean þ standard error of three inde-
pendent experiments. **P6 0.01 with respect to control cells.
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observe activity while Raf-1 protein is present, as has been
observed by others [29]. The problem of how ERK is acti-
vated by a process that ultimately destabilizes Raf-1 is not
solved, although the lack of interaction between Raf-1 and
Hsp90 could allow transient oligomerization and/or mem-
brane translocation, resulting in activation of Raf-1 before
its degradation. In fact, Hall-Jackson et al. have described
an equivalent situation with the p38/MAPK inhibitor
SB203580 [30].
Incubation of PC12 cells with GA induced of apoptosis, in
a manner dependent of JNK activity activation, as shown by
the fact that JNK inhibition results in survival of the cells.
The timing of activation of JNK, 3^4 h after Raf-1 disappear-
ance, is consistent with being this disappearance the trigger of
apoptosis. The fact that NGF does not protect the cells from
apoptosis poses the question of the ultimate trigger of death.
NGF mediates its action through the TrkA receptor and the
Ras/ERK signaling cascade, although signaling through the
phosphatidylinositol-3P-kinase (PI3K) pathway have also
been implicated [31]. The fact that GA-induced apoptosis is
dominant over NGF protection could mean that both path-
ways, Ras- and PI3K-mediated, are simultaneously needed for
survival of PC12 cells, or else, that although no activation of
ERK would be needed for survival, some other Raf-1-depen-
dent mechanism should exist.
It has been described that MEKK1, a MAP kinase kinase
kinase parallel to Raf-1, can activate both ERK and JNK
pathways, interacting with MEK1 [32] and Ras [33] on one
side, and SEK (the upstream kinase of JNK) [34,35] on the
other. The GA e¡ects we describe, activation of only ERK in
N2A cells and only JNK in PC12 cells, do not seem to be
related to MEKK1, as we should ¢nd activation of both path-
ways in both cell lines.
Although Raf-1 steady-state level modulation by inhibition
of Hsp90 could account for the e¡ects we observe, we have
also searched for possible e¡ects due to src protein kinase.
While v-src is much more sensitive to Hsp90 inhibition, recent
results show that this chaperone is also needed for proper
folding of c-src [10]. As our results show, however, c-src is
not involved in the observed phenotypes; since it has the
opposite e¡ect in N2A cells (inhibition of morphological dif-
ferentiation), and has no e¡ect in PC12 cells.
Note: When this manuscript was ready for submission, it
came to our attention that GA also induces apoptosis due to
Raf-1 destabilization in human luteinized granulosa cells [36].
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